Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model

Transplantation

Volumn 94, Issue 6, 2012, Pages 562-568

  Graves, Scott S ^a,b   Mathes, David W ^a,c,d   Georges, George E ^a,b   Kuhr, Christian S ^e   Chang, Jeff ^a,c   Butts, Tiffany M ^a   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Dog; Kidney allograft; Mixed hematopoietic chimerism; Nonmyeloablative conditioning regimen; Recipient lymphocyte infusion; Tolerance

Indexed keywords

CREATININE; CYCLOSPORIN; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENGRAFTMENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS PYELOGRAPHY; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE TRANSFER; NEPHRECTOMY; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RECIPIENT LYMPHOCYTE INFUSION; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DOGS; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; KIDNEY TRANSPLANTATION; LEUKOCYTE TRANSFUSION; MODELS, ANIMAL; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; WHOLE-BODY IRRADIATION;

EID: 84866729427     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182646bf1     Document Type: Article

References (31)

1. Kuhr CS, Allen MD, Junghanss C, et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002; 73: 148-7.
2. Kuhr CS, Yunusov M, Sale G, et al. Long-Term tolerance to kidney allografts in a preclinical canine model. Transplantation 2007; 84: 54-5.
3. Niemeyer GP, Welch JA, Tillson M, et al. Renal allograft tolerance in DLA-identical and haploidentical dogs after nonmyeloablative conditioning and transient immunosuppression with cyclosporine and mycophenolate mofetil. Transplant Proc 2005; 37: 457-9.
4. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-Term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 62-3.
5. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-Tumor effects. Blood 2001; 97: 339-0.
6. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 202-1.
7. Sorror ML, Sandmaier BM, Storer BE, et al. Long-Term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 187-4.
8. Kawai T, Cosimi AB, Sachs DH. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism (review). Curr Opin Organ Transplant 2011; 16: 36-6.
9. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 2010; 90: 160-7.
10. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 138-6.
11. Georges GE, Storb R, Thompson JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000; 95: 326-2.
12. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 304-8.
13. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 25-6.
14. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 35-3.
15. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-Term follow-up of recipients of combined human leukocyte antigenYmatched bone marrow and kidney transplantation for multiple myeloma with endstage renal disease. Transplantation 2011; 91: 67-2.
16. Suzuki MM, Cecka JM, Terasaki PI. Unrelated living donor kidney transplants (review). Br Med Bull 1997; 53: 85-4.
17. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection (review). Nat Rev Nephrol 2010; 6: 57-7.
18. Sachs DH, Sykes M, Kawai T, et al. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol 2011; 23: 16-5.
19. Nash RA, Yunusov M, Abrams K, et al. Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation. Am J Transplant 2009; 9: 103-7.
20. Stumpf AN, van der Meijden ED, van Bergen CA, et al. Identification of 4 new HLA-DRYrestricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood 2009; 114: 368-4.
21. Mielcarek M, Torok-Storb B, Storb R. Pharmacological immunosuppression reduces but does not eliminate the need for total-body irradiation in nonmyeloablative conditioning regimens for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 125-5.
22. Sorror ML, Leisenring W, Mielcarek M, et al. Intensified postgrafting immunosuppression failed to assure long-Term engraftment of dog leukocyte antigenYidentical canine marrow grafts after 1 gray total body irradiation. Transplantation 2008; 85: 102-3.
23. Wagner JL, Burnett RC, Storb R. Molecular analysis of the DLA DR region. Tissue Antigens 1996; 48: 54-9.
24. Wagner JL, Burnett RC, DeRose SA, et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996; 62: 87-6.
25. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci 1990; 40: 1-1.
26. Yu C, Ostrander E, Bryant E, et al. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 70-1.
27. Hilgendorf I, Weirich V, Zeng L, et al. Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. Vet Res Commun 2005; 29: 10-3.
28. Graves SS, Hogan W, Kuhr CS, et al. Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning. Blood 2007; 110: 41-8.
29. Sandmaier BM, Storb R, Santos EB, et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996; 87: 350-8.
30. Lupu M, Gooley T, Zellmer E, et al. Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation. J Vet Intern Med 2008; 22: 7-4.
31. Yunusov MY, Kuhr CS, Georges GE, et al. Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graft. Transplantation 2006; 82: 62-9.